PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Randox Laboratories Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Randox Laboratories Release a Ground-breaking Biochip Analyser for Onsite Drug Testing - This new development brings the well established Biochip Array Technology to the point of care market, offering a higher level of information than ever achieved from a rapid drug screen - Randox.com
Randox Laboratories Release a Ground-breaking Biochip Analyser for Onsite Drug Testing

 

NewswireToday - /newswire/ - Crumlin, Antrim, United Kingdom, 2011/05/26 - This new development brings the well established Biochip Array Technology to the point of care market, offering a higher level of information than ever achieved from a rapid drug screen - Randox.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Evidence MultiStat analyser is a fully automated, bench-top system with a state of the art touch screen interface, just one of its many ground breaking features. Users can benefit from the ability to detect up to 97 drug metabolites in one patient sample, in as little as twenty minutes. The straightforward procedure offers efficient testing which can be carried out with minimal training.

Randox have invested heavily in this advancement for onsite drug testing, in response to an increasing market demand. The Evidence MultiStat analyser utilises Biochip Array Technology, a multiplexing methodology which has been well-received in the clinical and forensic toxicology market over the last decade. Randox identified a gap in the market for a diagnostic grade point of care system, which could provide rapid testing without compromising quality and accuracy. Another unique feature of the analyser, which many onsite drug testing systems on the market currently lack is its ability to automatically generate quality control data, ensuring optimum performance and reliable results.

Primarily the Evidence MultiStat has been adopted in hospital emergency departments, with Biochip Array Technology ensuring fast and accurate results, leading to better patient treatment. In addition, the Randox range of Evidence biochip analysers offer an unrivalled test menu for toxicology screening and pain management.

For more information contact us at toxicology[.]randox.com.

About Randox
Headquartered in the United Kingdom, Randox Laboratories Ltd (randox.com) is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of forensic and clinical toxicology, clinical chemistry, cardiology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. A continuous strategy of innovation has allowed Randox to revolutionise technology for the toxicology market. Significant re-investment in Research and Development has seen the novel Biochip Array Technology adapt and evolve, with four analysers available for various settings.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Randox Laboratories Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Randox Laboratories Release a Ground-breaking Biochip Analyser for Onsite Drug Testing

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Charlotte Jess - Randox.com 
+44(0)28 4245 7832 marketing[.]randox.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Randox Laboratories Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Randox Laboratories Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)